If the cops don’t kill you, the “Covid” will.
Conflict has arisen between Australian citizens, health practitioners, and professors after a recent decision to ban health practitioners from prescribing ivermectin to COVID-19 patients. This most recent aggressive move by the Therapeutic Goods Administration (TGA) reflects a trend worldwide. National drug regulatory bodies are scrutinizing the drug even while in some cases public research institutes embark on large clinical trials. In the U.S. the National Institutes of Health (NIH) changed their ivermectin recommendation from use only for clinical trials to a more neutral stance (that is they do not recommend for or against due to lack of sufficient data). In the USA there is now concerted pressure indirectly from various government agencies (e.g. FDA and possibly NIH and CDC) to professional medical and pharmacy societies and boards to send out cautionary messages to their membership. In the USA that message is working as providers around the country share with TrialSite that it has become exceedingly difficult to fill an off-label ivermectin prescription. Australia has taken a far more aggressive tact—essentially banning GPs from prescribing for COVID-19.